CLINICAL_TRIALS
trial_result
· 2024-10-28
Clinical Trial Update: Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) [Phase 3]
Summary
A Phase 3 RESTORE trial evaluating a Mirum Pharmaceuticals therapy for Cerebrotendinous Xanthomatosis has completed, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: CTX | Phase 3 | Status: COMPLETED | Results posted: 2024-10-28